Frontier Biotech and GSK sign USD 1b. exclusive licensing deal for siRNA kidney disease therapies

# Frontier Biotech GSK Licensing Agreement: USD 1 Billion siRNA Deal Targets Kidney Diseases Frontier Biotechnologies Inc., a Nanjing, China-headquartered biopharma company, [announced](https://www.prnewswire.com/news-releases/frontier-biotech-and-gsk-enter-global-exclusive-licensing-agreement-for-small-interfering-rna-therapeutics-302695615.html) an exclusive licensing agreement with GSK, the London-based global pharmaceutical company, granting GSK worldwide rights to develop, manufacture, and commercialize two of Frontier Biotech's small interfering RNA therapeutics pipeline products. The deal covers one asset at the Investigational New Drug application stage and a second preclinical candidate, both targeting kidney diseases with an inflammatory component. Under the terms of the Frontier Biotechnologies GSK deal, GSK obtains exclusive global rights to both programs, while Frontier Biotech retains responsibility for early-stage advancement — conducting a Phase I clinical trial in China for the IND-stage asset and completing IND-enabling activities for the preclinical candidate before handing both programs to GSK for all subsequent development, regulatory filings, and commercialization. The financial structure of the GSK exclusive licensing agreement includes a USD 40 million upfront payment to Frontier Biotech, with up to USD 963 million in additional success-based development, regulatory, and commercial milestone payments across the two programs. Frontier Biotech is also eligible for tiered royalties on worldwide net sales, though specific royalty rates were not disclosed. The total potential deal value therefore exceeds USD 1 billion before royalties. No equity investment by GSK in Frontier Biotech was described as part of the transaction. The milestone-heavy structure is consistent with the early stage of both assets, where the bulk of economic value is contingent on clinical and commercial progress under GSK's stewardship. ## Deal Context The two assets covered by the agreement are siRNA therapeutics — a modality within the broader oligonucleotide drug class that works by silencing the expression of specific disease-associated genes through RNA interference. Frontier Biotech and GSK did not disclose the specific molecular targets or compound designations for either asset in the public announcement. Kaivan Khavandi, SVP and Global Head of Respiratory, Immunology and Inflammation R&D at GSK, described the two programs as potential first-in-class oligonucleotide therapies with application across multiple kidney diseases, aligned with GSK's focus on platform technologies and inflammatory-driven disease. The absence of disclosed targets prevents precise mapping to clinical-stage competitors or specific disease indications such as IgA nephropathy, lupus nephritis, diabetic kidney disease, or focal segmental glomerulosclerosis. Frontier Biotech's siRNA pipeline is a newer strategic direction for the company, which built its commercial business around Aikening (albuvirtide), the first long-acting injectable HIV fusion inhibitor approved in China. The company's broader siRNA portfolio spans antiviral, osteoporosis, metabolic, and hyperlipidemia indications at various preclinical and early clinical stages. Frontier Biotech has separately disclosed work on FB7011, an siRNA candidate targeting MASP-2 in the complement lectin pathway for IgA nephropathy, though it has not been confirmed whether this asset is among the two licensed to GSK. The siRNA therapeutics licensing agreement with GSK represents Frontier Biotech's first deal with the UK-based company and is the largest out-licensing transaction the Chinese firm has completed to date. For GSK, the deal adds two early-stage RNA drug candidates to its immunology pipeline and represents a commitment to the siRNA modality within its inflammation and kidney disease strategy. GSK has been active in adjacent nucleic acid modalities, including antisense oligonucleotides and mRNA, but the Frontier Biotech RNA drug agreement is among the company's more visible moves into siRNA specifically. The transaction follows GSK's broader pattern of in-licensing platform-stage assets from smaller companies to feed its late-stage development engine. The deal is the first partnership between the two companies. No prior licensing agreements, research collaborations, or other commercial arrangements between Frontier Biotech and GSK have been publicly reported. ## Competitive and Industry Landscape The siRNA and oligonucleotide licensing space has seen sustained deal activity in recent years, driven by the clinical and commercial validation of the modality through approved products such as Alnylam Pharmaceuticals' patisiran and inclisiran (the latter now commercialized by Novartis). Several recent transactions provide context for the Frontier Biotech GSK agreement, though direct same-target comparisons are not possible given the undisclosed targets. In July 2022, Roche [licensed](https://www.fiercebiotech.com/biotech/roche-hands-over-55m-licensing-rights-ionis-kidney-disease-candidate) IONIS-FB-LRx, an antisense oligonucleotide targeting complement factor B for IgA nephropathy, from Ionis Pharmaceuticals for a USD 55 million upfront payment. That deal involved a later-stage asset (advancing toward Phase III) and a different modality (ASO rather than siRNA), but it sits within the same kidney disease and complement biology neighborhood. In March 2020, AstraZeneca and Silence Therapeutics [entered](https://silence-therapeutics.com/investors/press-releases/press-releases-details/2020/Collaboration-with-AstraZeneca/default.aspx) a multi-target siRNA discovery collaboration spanning cardiovascular, renal, and metabolic disease areas, with USD 80 million in upfront and equity payments and up to USD 400 million in milestones per target plus tiered royalties. That platform-level collaboration illustrates the scale of investment large pharma companies have committed to siRNA discovery, though its multi-target scope differs from the two-asset structure of the Frontier Biotech deal. More recently, in May 2025, CRISPR Therapeutics and Sirius Therapeutics [announced](https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-and-sirius-therapeutics-announce-multi-target-collaboration-to-develop-novel-sirna-therapies) a multi-target siRNA collaboration that included SRSD107, a Factor XI siRNA for thromboembolic disorders, with USD 25 million in cash and USD 70 million in equity upfront, plus additional contingent milestones. While the therapeutic area differs, the deal structure — combining upfront cash with equity and back-ended milestones — reflects a common pattern in siRNA partnering. The kidney disease space specifically has attracted oligonucleotide and RNA-based approaches across several targets. Without confirmation of the Frontier Biotech targets, the following assets represent active clinical-stage siRNA or oligonucleotide programs in kidney indications: - Alnylam Pharmaceuticals' cemdisiran (ALN-CC5), an siRNA targeting complement C5, in [Phase II](https://clinicaltrials.gov/study/NCT03841448) for IgA nephropathy and other complement-mediated kidney diseases - Ionis Pharmaceuticals / Roche's IONIS-FB-LRx (now donidalorsen-adjacent program), an ASO targeting complement factor B, in Phase III for IgA nephropathy - Arrowhead Pharmaceuticals' ARO-C3, an siRNA targeting complement C3, in [Phase I/II](https://clinicaltrials.gov/study/NCT05083364) for complement-mediated diseases including renal indications - Silence Therapeutics' SLN124, an siRNA targeting TMPRSS6, in Phase I for iron-loading anemias with renal complications under evaluation The USD 40 million upfront payment in the Frontier Biotech deal is within the range observed for early-stage siRNA out-licensing transactions, where the IND-stage and preclinical status of the assets limits the upfront component relative to later-stage deals. The up to USD 963 million milestone tail is large but consistent with two-program structures where commercial milestones account for the majority of back-ended value. The deal sits within a broader trend of Chinese biotech companies executing outbound licensing transactions with global pharma partners — a reversal of the historically predominant license-in model in China's biopharma sector. GSK's decision to source siRNA assets from a Chinese originator for its global immunology pipeline reflects both the maturation of China's nucleic acid drug discovery capabilities and the continued appetite among large pharma companies for external innovation in the RNA therapeutics space. The specific clinical and commercial trajectory of the two programs will depend on data from Frontier Biotech's Phase I study in China and subsequent GSK-led global development, timelines for which have not been disclosed. --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/frontier-biotech-gsk-and-sign-usd-1b-exclusive)